Bacterial bismuth-binding proteins (null)

Bacterial bismuth-binding proteins are a heterogeneous group of bacterial enzymes, redox proteins, structural proteins, and metalloproteins that bind bismuth ions introduced by therapeutic bismuth compounds. Bismuth targets key metabolic and stress response pathways within bacteria by covalently or coordinatively binding to specific protein residues, notably cysteine and histidine, within active sites or metal-binding motifs. This binding disrupts function in critical pathways, such as the TCA cycle (energy production), electron transport chain (oxidative phosphorylation), protein synthesis (translation), and stress responses (redox, nickel and iron homeostasis, urease activity, protein folding). Bismuth binding also acts as a resistance breaker, synergistically enhancing the effects of antibiotics by impairing bacterial efflux pumps and metabolic resilience, making it especially valuable for treating drug-resistant infections including *Burkholderia cepacia*, *Helicobacter pylori*, and *Pseudomonas aeruginosa*. While the term does not describe a single molecular entity, it encompasses multiple druggable bacterial targets whose collective inhibition underlies the clinical efficacy of bismuth-based antimicrobials.

Other names

Bismuth-binding proteinsBi-binding proteinsBacterial metalloproteinsSpecific examples: Urease (UreA/UreB)malate dehydrogenase (MDH)succinyl coenzyme A synthetase (SCS)terminal oxidases (CyoC, CydA)HspAHspBDnaKNDM-1Ef-TufumaraseHpn

Enzyme inhibition via bismuth ion binding, often at cysteine residues, disrupting metabolic and/or redox function Metal ion displacement (e.g., replacement of Zn or Ni with Bi) Impairment of electron transport chain by targeting/inactivation of terminal oxidases (CyoC, CydA, Nuo NADH dehydrogenase) Disruption of TCA cycle via binding to enzymes such as MDH, AceB, SCS Inhibition of protein synthesis via ribosomal protein binding Blocking bacterial stress and defense pathways (e.g., oxidative/redox homeostasis, urease activity) Efflux pump inhibition, increasing intracellular antibiotic concentrations